Pauline is an associate in our Patents & Innovation team. She advises clients on various matters related to intellectual property and has a keen interest in life sciences. Pauline primarily focuses on litigation and has gained international experience by pleading before the Unified Patent Court (UPC).
She supports national and international clients in complex patent disputes across a range of technical fields, helping them navigate the challenges of enforcement and defense. Since 2024, Pauline has been a UPC representative, representing multiple clients before the UPC courts and gaining valuable insight into the specific challenges linked to this unprecedented system. With a practical mindset and a strategic approach, she is committed to securing the best possible outcomes for her clients.
UPC litigation in life sciences: seven early takeaways for the pharma, biotech and medical devices sectors
The Unified Patent Court (UPC) has become a crucial forum for life sciences patent litigation. Early rulings show strict claim interpretation, careful review of European Patent Office oppositions, and limits on the Bolar exemption. The UPC has clarified infringement tests for second medical use claims and considers patient interests in injunctions. These developments emphasise precise patent strategy, regulatory alignment, and proactive risk management for pharma, biotech, and medical device sectors.
作者 Yolandi Coetzee 以及 Pauline Springorum
1 / 5 观点
作者 Mareike Christine Gehrmann 以及 Carla Nelles, LL.M. (Amsterdam)
作者 Katie Chandler 以及 Esha Marwaha
作者 Graham Hann 以及 Kelly Burke
作者 Alexander Schmalenberger, LL.B. 以及 Nathalie Koch, LL.M. (UC Hastings)